Inhale-3 Study Results to Be Presented During a 90-Minute Symposium on Saturday, June 22

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions June 5, 2024 10:45 AM EDT 17-week endpoint results comparing Afrezza® head-to-head with multiple daily injections (MDI) and insulin pumps INHALE-3 Study Protocol Chair Dr. Irl. B. [...] and WESTLAKE VILLAGE, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced that the 17-week endpoint results from the INHALE-3 study will be presented during a 90-minute symposium and livestream o [...] Hirsh and the investigational team and will be moderated by Jaeb Center founder Dr. Roy W. Beck. [...] Weinstock Study Results II: Primary Efficacy, Safety, and Quality of Life Outcomes – Dr. Carol J. [...] Levy Study Results III: Effect of Inhaled Insulin-Degludec Compared with AID and in Subgroups According to Participant Characteristics – Dr. [...] Grazia Aleppo Critique of Study Design and Results – by Dr. Irl B. [...] Hirsch Use of Afrezza in Clinical Practice – by Dr. [...] Thomas Blevins Question and Answer Session – Moderated by Dr. Roy W. [...] Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation, depending on the target indication. [...] With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.